Table 4.
Causes of ALT >100 U/L in HBV-HCC patients on ICI treatment
N (%) | HBV DNA ≤100 IU/mL on NUCs (n=10) | HBV DNA >100 IU/mL on NUCs (n=11) | Patients with HBV without NUCs (n=2) |
Tumor progression | 9 (90.0) | 10 (90.9) | 1 (50.0) |
HBV reactivation | 0 | 0 | 1 (50.0) |
iRAE hepatitis | 1 (10.0) | 1 (9.1) | 0 (0) |
ALT, alanine aminotransferase; HBV, hepatitis B virus; ICI, immune checkpoint inhibitor; iRAE, immunotherapy related adverse event; NUCs, nucleos(t)ide analogs.